



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Azilect®

Common Name: Rasagiline

PDL Category: Anti-Parkinsonian Drug

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Eldepryl® Cap 5mg	Non-Preferred
Selegiline Cap 5mg	Preferred

Summary

Indications and Usage: Parkinson's Disease

Dosage Forms: Tablets; 0.5mg and 1mg

Recommended Dosage: 1mg PO QD; start 0.5mg PO QD if used with levodopa

Common Adverse Drug Reactions: Joint pain, dyspepsia, dyskinesia, nausea, vomiting, dry mouth, fatigue

Contraindications: Hepatic dysfunction, sympathomimetic use, serotonergic use, pheochromocytoma, ingestion of foods high in tyramine content, coadministration with MAOIs and CYP1A2 inhibitors

Manufacturer: Teva Pharmaceutical Industries Ltd.

Analysis: Azilect® is the first once-daily medication approved for the treatment of Parkinson's Disease. It can be used as monotherapy in the early stages of Parkinson's, or in combination with levodopa in more advanced cases. Clinical studies suggest that the once-a-day formulation of Azilect® reduces "off" time and Parkinson's motor symptoms. Other medications within this class, as well as other classes of anti-Parkinson's drugs, are used to reduce "off" time associated with the disease that appear on the Preferred Drug List as preferred products and are more cost effective. In April, 2006, the American Academy of Neurology published a review, "Treatment of Parkinson Disease With Motor Fluctuations and Dyskinesia" and asserted that "the available evidence does not establish superiority of one medicine over another in reducing off time".

IME Recommendation:

<input type="checkbox"/>	Preferred Drug	<input type="checkbox"/>	Recommended Drug
<input checked="" type="checkbox"/>	Non-Preferred Drug	<input type="checkbox"/>	Non-Recommended Drug
<input type="checkbox"/>	Preferred Drug with Conditions		